<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02740179</url>
  </required_header>
  <id_info>
    <org_study_id>2016P000464</org_study_id>
    <nct_id>NCT02740179</nct_id>
  </id_info>
  <brief_title>Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)</brief_title>
  <official_title>Mineralocorticoid Receptor Antagonism for Cardiovascular Health in HIV--The MIRACLE HIV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV-infected individuals treated with antiretroviral medications are living longer, but have&#xD;
      an increased risk of heart disease when compared to non-HIV-infected individuals. A hormone&#xD;
      called aldosterone, which regulates blood pressure and sodium balance, is elevated in the HIV&#xD;
      population in association with with increased belly fat and altered glucose metabolism.&#xD;
      Elevations in aldosterone hormone may also be associated with abnormal blood flow,&#xD;
      inflammation, and coronary plaque in the heart. This study is being conducted to evaluate&#xD;
      whether therapies to reduce the actions of aldosterone may decrease the burden and&#xD;
      progression of heart disease in the HIV population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 12 month randomized, placebo controlled study enrolling HIV-infected individuals&#xD;
      with no known history of cardiovascular disease. Eplerenone is a mineralocorticoid receptor&#xD;
      antagonist, which can block aldosterone activation. This medication is approved by the FDA&#xD;
      for high blood pressure and heart failure. This study aims to investigate the effect of&#xD;
      eplerenone on other measures of cardiovascular disease in HIV. Using PET, MRI, and CT imaging&#xD;
      technology, this study will evaluate whether eplerenone can improve coronary flow reserve and&#xD;
      myocardial inflammation/fibrosis, in addition to atherosclerotic plaque build-up among the&#xD;
      HIV population. The study also includes teaching on lifestyle modification to promote a&#xD;
      healthy diet and exercise program.There are 3 overnight visits in addition to safety visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Flow Reserve</measure>
    <time_frame>12 Months</time_frame>
    <description>Coronary Flow Reserve measured via Cardiac Positron Emission Tomography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial Inflammation</measure>
    <time_frame>12 Months</time_frame>
    <description>Myocardial Inflammation measured by extracellular volume fraction via Cardiac Magnetic Resonance Imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coronary Plaque</measure>
    <time_frame>12 Months</time_frame>
    <description>Coronary Plaque measured via Coronary Computed Tomography Angiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Vascular Dysfunction</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Systemic Inflammation</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Immune Activation</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Subclinical Injury</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Fibrosis</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Inflammation</measure>
    <time_frame>12 Months</time_frame>
    <description>Arterial Inflammation measured via Aortic Positron Emission Tomography/Computed Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Arterial Inflammation</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenone 50 mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>Eplerenone 50mg by mouth twice daily</description>
    <arm_group_label>Eplerenone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo by mouth twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle Modification</intervention_name>
    <description>Counseling regarding diet and healthy activity</description>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages 40-65 years&#xD;
&#xD;
          2. Antiretroviral use (ART) &gt;12 months and HIV viral load &lt;100 copies/mL&#xD;
&#xD;
          3. VAT&gt; 110cm2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Antihypertensive use including, ACE Inhibitor, ARB, MR blockade, diuretic, potassium&#xD;
             (K) supplementation; or BP&gt;140/90 mmHg. Stable use (&gt;3 months) of beta-blockers or&#xD;
             calcium channel blockers (CCB) (except verapamil) is allowed.&#xD;
&#xD;
          2. Unstable statin use &lt;12 months. Stable use (&gt;12 months) is allowed.&#xD;
&#xD;
          3. Use of full dose ritonavir, nelfinavir, clarithromycin, and other strong inhibitiors&#xD;
             of CYP3A4, as well as CYP3A4 inducers.&#xD;
&#xD;
          4. Continuous oral steroid use (equivalent to prednisone &gt; 5 mg daily) within the last 3&#xD;
             months.&#xD;
&#xD;
          5. Uncontrolled diabetes requiring insulin and/or HbA1c &gt; 7.5%.&#xD;
&#xD;
          6. Creatinine (Cr) &gt; 1.5 mg/dL or estimated GFR&lt;60 mL/min/1.73m2.&#xD;
&#xD;
          7. K &gt; 5.5 mEq/L.&#xD;
&#xD;
          8. Hemoglobin &lt; 10 g/dL.&#xD;
&#xD;
          9. Known liver disease or ALT &gt;3x ULN.&#xD;
&#xD;
         10. History of congestive heart failure, stroke, myocardial infarction, or known coronary&#xD;
             artery disease.&#xD;
&#xD;
         11. Pregnant, actively seeking pregnancy or breastfeeding.&#xD;
&#xD;
         12. Estrogen, progestin derivative, or other sex steroid use within last 3 months. Stable&#xD;
             physiologic testosterone replacement (&gt; 3 months) is acceptable.&#xD;
&#xD;
         13. Current bacterial or other infections.&#xD;
&#xD;
         14. Active substance abuse.&#xD;
&#xD;
         15. Significant radiation exposure over the course of the year prior to randomization&#xD;
             (e.g., radiation therapy, PCI, catheter ablation of arrhythmia) within 12 months of&#xD;
             randomization.&#xD;
&#xD;
         16. Previous reaction or contraindication to iodine-containing contrast media and&#xD;
             gadolinium.&#xD;
&#xD;
         17. Coronary artery luminal narrowing &gt;70% on coronary CTA.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Srinivasa S, Fitch KV, Wong K, Torriani M, Mayhew C, Stanley T, Lo J, Adler GK, Grinspoon SK. RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients. J Clin Endocrinol Metab. 2015 Aug;100(8):2873-82. doi: 10.1210/jc.2015-1461. Epub 2015 Jun 18.</citation>
    <PMID>26086328</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 7, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven K. Grinspoon, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Eplerenone</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Mineralocorticoid Receptor Antagonist</keyword>
  <keyword>Coronary Vasculature</keyword>
  <keyword>Myocardial Inflammation</keyword>
  <keyword>Myocardial Fibrosis</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Aldosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

